Skip to main content
Erschienen in: International Urogynecology Journal 4/2015

01.04.2015 | Original Article

Impact of anticholinergic load on bladder function

verfasst von: Jacquia F. De La Cruz, Cassandra Kisby, Jennifer M. Wu, Elizabeth J. Geller

Erschienen in: International Urogynecology Journal | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Our aim was to evaluate the impact of anticholinergic load on urinary retention based on postvoid residual (PVR) on micturition study. Secondary objectives were to assess the effect of anticholinergic load on other urodynamic parameters.

Methods

This was a retrospective cohort study of women who underwent urodynamics (UDS) at one academic institution. All medications being taken by the women at the time of UDS were scored using the anticholinergic risk scale (ARS). This validated scale assigns rank scores to each medication based on its anticholinergic potential. Women were dichotomized into two anticholinergic cohorts: low (0–1) or high (≥2) ARS scores.

Results

During the study period, 599 women underwent UDS. ARS scores ranged from 0 to 8, with 440 (73.5 %) having low (≤1) and 159 (26.5 %) having high (≥2) scores. For our primary outcome of micturition PVR, there was no difference between low and high ARS groups (66.8 ± 108.6 ml vs. 78.6 ± 121.0 ml, p = 0.25). There was also no difference between ARS groups in other voiding function parameters. Sensitivity analyses did demonstrate a difference in micturition PVR, with ARS 0–4 (n = 583) vs. ARS ≥ 5 (n = 16): 68.3 ± 109.1 ml vs. 127.5 ± 185.7 (p < 0.01) ,as well as maximum cystometric capacity (MCC): 420.8 ± 181.3 ml vs. 526.1 ± 252.4 ml (p = 0.02).

Conclusions

Despite the prevalence and risks associated with the use of medications with anticholinergic properties, a cumulative effect on bladder function was only demonstrated with very high anticholinergic risk scores of ≥5.
Literatur
1.
Zurück zum Zitat Geller EJ, Crane AK, Wells EC et al (2012) Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig 32(10):697–705CrossRefPubMedCentralPubMed Geller EJ, Crane AK, Wells EC et al (2012) Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig 32(10):697–705CrossRefPubMedCentralPubMed
2.
Zurück zum Zitat Milsom I, Kaplan SA, Coyne KS et al (2012) Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 80(1):90–96CrossRefPubMed Milsom I, Kaplan SA, Coyne KS et al (2012) Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 80(1):90–96CrossRefPubMed
3.
Zurück zum Zitat Kay GG, Abou-Donia MB, Messer WS Jr et al (2005) Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 53(12):2195–2201CrossRefPubMed Kay GG, Abou-Donia MB, Messer WS Jr et al (2005) Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 53(12):2195–2201CrossRefPubMed
4.
Zurück zum Zitat Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148(5):565–578CrossRefPubMedCentralPubMed Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148(5):565–578CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Boustani M (2008) ea. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 4(3):311–320CrossRef Boustani M (2008) ea. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 4(3):311–320CrossRef
6.
Zurück zum Zitat Carnahan RM, Lund BC, Perry PJ et al (2006) The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 46(12):1481–1486CrossRefPubMed Carnahan RM, Lund BC, Perry PJ et al (2006) The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 46(12):1481–1486CrossRefPubMed
7.
Zurück zum Zitat Natalin R, Lorenzetti F, Dambros M (2013) Management of OAB in those over age 65. Curr Urol Rep 14(5):379–385CrossRefPubMed Natalin R, Lorenzetti F, Dambros M (2013) Management of OAB in those over age 65. Curr Urol Rep 14(5):379–385CrossRefPubMed
8.
Zurück zum Zitat Rudolph JL, Salow MJ, Angelini MC et al (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168(5):508–513CrossRefPubMed Rudolph JL, Salow MJ, Angelini MC et al (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168(5):508–513CrossRefPubMed
9.
Zurück zum Zitat Duran CE, Azermai M, Vander Stichele RH (2013) Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 69(7):1485–1496CrossRefPubMed Duran CE, Azermai M, Vander Stichele RH (2013) Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 69(7):1485–1496CrossRefPubMed
10.
Zurück zum Zitat Hanlon JT, Schmader KE, Ruby CM et al (2001) Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 49(2):200–209CrossRefPubMed Hanlon JT, Schmader KE, Ruby CM et al (2001) Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 49(2):200–209CrossRefPubMed
11.
Zurück zum Zitat Scheife R, Takeda M (2005) Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27(2):144–153CrossRefPubMed Scheife R, Takeda M (2005) Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27(2):144–153CrossRefPubMed
12.
Zurück zum Zitat Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R (2008) Drug-induced urinary retention: incidence, management and prevention. Drug Saf : Int J Med Toxicol Drug Experience 31(5):373–388CrossRef Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R (2008) Drug-induced urinary retention: incidence, management and prevention. Drug Saf : Int J Med Toxicol Drug Experience 31(5):373–388CrossRef
13.
Zurück zum Zitat Walter PJ, Dieter A, Siddiqui NY et al (2014) Perioperative anticholinergic medications and risk of catheterization after urogynecologic procedures. Female Pelvic Med Reconstr Surg 20(3):163–167CrossRefPubMed Walter PJ, Dieter A, Siddiqui NY et al (2014) Perioperative anticholinergic medications and risk of catheterization after urogynecologic procedures. Female Pelvic Med Reconstr Surg 20(3):163–167CrossRefPubMed
14.
Zurück zum Zitat Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5–26CrossRefPubMed Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5–26CrossRefPubMed
15.
Zurück zum Zitat Jonas U, Hofner K, Madersbacher H et al (1997) Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. Int Study Group World J Urol 15(2):144–151CrossRef Jonas U, Hofner K, Madersbacher H et al (1997) Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. Int Study Group World J Urol 15(2):144–151CrossRef
16.
Zurück zum Zitat Carnahan RM, Lund BC, Perry PJ et al (2002) The relationship of an anticholinergic rating scale with serum anticholinergic activity in elderly nursing home residents. Psychopharmacol Bull 36(4):14–19PubMed Carnahan RM, Lund BC, Perry PJ et al (2002) The relationship of an anticholinergic rating scale with serum anticholinergic activity in elderly nursing home residents. Psychopharmacol Bull 36(4):14–19PubMed
17.
Zurück zum Zitat Kersten H, Molden E, Willumsen T et al (2013) Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Br J Clin Pharmacol 75(3):842–849PubMedCentralPubMed Kersten H, Molden E, Willumsen T et al (2013) Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Br J Clin Pharmacol 75(3):842–849PubMedCentralPubMed
18.
Zurück zum Zitat Pasina L, Djade CD, Lucca U et al (2013) Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging 30(2):103–112CrossRefPubMed Pasina L, Djade CD, Lucca U et al (2013) Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging 30(2):103–112CrossRefPubMed
19.
Zurück zum Zitat Tanaka Y, Masumori N, Tsukamoto T (2010) Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. Int J Urol 17(9):796–800CrossRefPubMed Tanaka Y, Masumori N, Tsukamoto T (2010) Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. Int J Urol 17(9):796–800CrossRefPubMed
20.
Zurück zum Zitat Hsiao SM, Chang TC, Wu WY et al (2011) Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 37(8):1084–1091CrossRefPubMed Hsiao SM, Chang TC, Wu WY et al (2011) Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res 37(8):1084–1091CrossRefPubMed
21.
Zurück zum Zitat Wu WY, Hsiao SM, Chang TC et al (2011) Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction. J Obstet Gynaecol Res 37(5):436–441CrossRefPubMed Wu WY, Hsiao SM, Chang TC et al (2011) Changes in urodynamic parameters after tolterodine treatment for female overactive bladder syndrome with or without voiding dysfunction. J Obstet Gynaecol Res 37(5):436–441CrossRefPubMed
22.
Zurück zum Zitat Wagg A, Malone-Lee J (2003) Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU Int 92(9):969–971CrossRefPubMed Wagg A, Malone-Lee J (2003) Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU Int 92(9):969–971CrossRefPubMed
Metadaten
Titel
Impact of anticholinergic load on bladder function
verfasst von
Jacquia F. De La Cruz
Cassandra Kisby
Jennifer M. Wu
Elizabeth J. Geller
Publikationsdatum
01.04.2015
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 4/2015
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-014-2548-x

Weitere Artikel der Ausgabe 4/2015

International Urogynecology Journal 4/2015 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.